📅 Dog Rabies Vaccine: Recommended Timeline 📅 💉 1 Year Rabies Vaccine 💉 Safe to Start: 12 Weeks Booster: 1 Year from Date Given 💉 3 Year Rabies Vaccine... | By University Drive Veterinary Hospital | Facebook
![Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a2-F-large.gif?_=74286)
Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR
Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil | PLOS Neglected Tropical Diseases
![Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. | Semantic Scholar Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6e43c59eb34eb6feddd151800940fae399ba3983/7-Table1-1.png)
Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. | Semantic Scholar
![Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial - The Lancet Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial - The Lancet](https://www.thelancet.com/cms/attachment/2108947429/2082713414/gr1.gif)
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial - The Lancet
![Figure. Rabies post-exposure prophylaxis: terrestrial animal exposures | The Australian Immunisation Handbook Figure. Rabies post-exposure prophylaxis: terrestrial animal exposures | The Australian Immunisation Handbook](https://immunisationhandbook.health.gov.au/sites/default/files/2021-09/Figure-Rabies-PEP-terrestrial-animal-exposures.png)
Figure. Rabies post-exposure prophylaxis: terrestrial animal exposures | The Australian Immunisation Handbook
![A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study - The Lancet Infectious Diseases A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/712a2b2e-6eb1-4555-b7a1-a503644d4a02/gr1.gif)